Inspire Medical Systems, Inc. (INSP) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Solid margins ⢠Premium pricing INSP has a strong balance sheet, solid profitability, and healthy cash flow, but its premium valuation and shareholder cash outflows mean the stock already prices in much of that strength.
Price Behavior
Key Price Behavior Insights: ⢠Mid-50s support ⢠Near-term resistance ⢠Choppy rebound Support Level: $55â$56 Resistance Level: $57.5â$58.0 INSP has recovered over the last month into the mid-50s and remains constructively supported near $55â$56, but repeated rejection under $57.5â$58 keeps the rebound from turning into a confirmed breakout.
Sentiment & News
Key News Insights: ⢠Earnings catalyst ⢠Strong demand ⢠Reimbursement risk INSP is heading into its next earnings report with upbeat momentum from strong demand, improving margins, and growing attention to potential estimate beats, though reimbursement and policy headwinds remain a risk.
AI Summary
INSP is shifting from a pure high-growth medtech story to a reimbursement-and-launch execution story, where the real upside depends on Inspire V's coding clarity translating into adoption and margin leverage, while the main risk is that elevated spend and reimbursement friction keep growth and valuation from re-rating.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |